The IPECAD Alzheimer’s disease model (Green et al, 2019) has been developed by the IPECAD Modelling Group as a framework to model disease progression across Alzheimer’s disease (AD) and to assess the costs and outcomes associated with the condition, and the cost-effectiveness of interventions for people affected by AD, using the scenario of a future disease modifying therapies (DMT) for people with mild cognitive impairment (MCI) due to AD.
A description of the model (version 1.0) entitled “Assessing cost-effectiveness of early intervention in Alzheimer’s disease: An open-source modeling framework” is published open-access in the journal Alzheimer’s and Dementia: the journal of the Alzheimer’s Association (Alzheimers Dement 2019 Oct;15(10):1309-1321 doi: 10.1016/j.jalz.2019.05.004 or PubMed).
You can use this open-source model for free under the Creative Commons Attribution-ShareAlike 4.0 International Public License.
We host a version history developed by the IPECAD Modelling Group below.
We provide a listing of self-reported external applications of the model below to endorse transparency.
Request a download link
External applications & involvements
2020 October: publication Jun H, Cho SK, Aliyev ER, Mattke S, Suen SC. How Much Value Would a Treatment for Alzheimer’s Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy. Curr Alzheimer Res. 2020 Dec 3. doi: 10.2174/1567205017666201203121907. PMID: 33272181
2020 October: Bengt Winblad (IPECAD member) has provided general advise for Grifols International – AMBAR commercial Development who have requested the IPECAD model version 1.0.
2020 May-August: Ron Handels (IPECAD member) has guided two master students who have applied the IPECAD model version 1.0 in their internship (Health, Policy and Management master’s program at Maastricht University).
Version history
Version 1.1
1 March 2021
This version was developed as part of the IPECAD modelling workshop challenge 2020 (see https://ipecadgroup.wordpress.com/workshop/). Alongside the Excel version a version was coded in R.
Miscellaneous
- Addition of input (functionality) on ‘Treatment Discontinuation (waning)’. For Excel version see sheet ‘Inputs’ cell ‘D11’ is 10% corresponding to text “Treatment discontinuation/waning (per year)”.
- Additional reporting by states / disease stages including use of ‘half-cylce correction’ [prior version 1.0 did not report results on disease progression using half-cycle correcction]. For Excel version see for example sheet “Usual Care COhort” cell ‘BV9’.
- Included reporting for results and CEA outputs over a 10-year time horizon. For Excel version see additional tables/reporting on sheets “Usual Care Cohort” and “Treatment Cohort” e.g. from cell ‘DJ19’, and also in sheet “Results” e.g. from cells ‘H11’ & ‘BJ49’.
- Includes additional reporting, on time (person years) in disease stages, with half-cycle correction; to facilitate reporting of trace by severity stage over time. For Excel version see for example in sheet “Outputs” cells ‘X2’ and ‘AW2’.
Bug fixes
none
Version 1.0
8 August 2019
Development group
Anders Gustavsson (Karolinska Institutet, Sweden)
Colin Green (Biogen UK; University of Exeter, UK; Karolinska Institutet, Sweden)
Ron Handels (Maastricht University, Netherlands; Karolinska Institutet, Sweden)
Linus Jönsson (Karolinska Institutet, Sweden)
Anders Sköldunger (Karolinska Institutet, Sweden)
Anders Wimo (Karolinska Institutet, Sweden)
Bengt Winblad (Karolinska Institutet, Sweden)
Former members:
Andreas Karlson (Karolinska Institutet, Sweden) (2019-2020)
